Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.
Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.
Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on the phase II clinical data for KarXT, published in the New England Journal of Medicine.
